Form 8-K - Current report:
SEC Accession No. 0001193125-22-112139
Filing Date
2022-04-21
Accepted
2022-04-21 08:00:55
Documents
13
Period of Report
2022-04-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d329540d8k.htm   iXBRL 8-K 35311
2 EX-10.1 d329540dex101.htm EX-10.1 43408
  Complete submission text file 0001193125-22-112139.txt   209952

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA srpt-20220419.xsd EX-101.SCH 2893
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE srpt-20220419_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srpt-20220419_pre.xml EX-101.PRE 10837
7 EXTRACTED XBRL INSTANCE DOCUMENT d329540d8k_htm.xml XML 3230
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14895 | Film No.: 22839704
SIC: 2834 Pharmaceutical Preparations